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Intraoperative assessment of axillary lymph nodes in
patients with breast cancer
Time to abandon?
J Michael Dixon professor of surgery 1, Emiel Rutgers clinical director 2, Kelly K Hunt professor of
surgical oncology 3
1Edinburgh Breast Unit, Western General Hospital, Edinburgh, UK; 2Netherlands Cancer Institute, Amsterdam, Netherlands; 3University of Texas
MD Anderson Cancer Center, Houston, TX 77030, USA
The main advantage of intraoperative assessment of axillary
lymph nodes in patients having surgery for breast cancer is that
metastatic disease can be diagnosed and removed in a single
operation. However, there are several disadvantages that have
cast doubt on its use. These include concerns about its accuracy
and the uncertainty that all patients with diseased sentinel nodes
need additional treatment.
Accuracy questioned
Several methods have been used for intraoperative assessment
of axillary nodes, including frozen section analysis, touch
preparation cytology, and one step nucleic acid amplification.
The National Institute for Health and Care Excellence (NICE)
approved one step nucleic acid amplification in 2011, and it is
the most widely used axillary staging method in the United
Kingdom.1
A recent meta-analysis has raised doubts about the ability of
one step nucleic acid amplification to accurately determine the
extent of axillary node involvement.2 The method is based on
the measurement of messenger RNA for cytokeratin 19,
expression levels of which vary between and within cancers,
with copy numbers ranging from 4700 to 140 000 copies per
microlitre. The meta-analysis concluded that the wide range of
copy numbers in a fixed tumour volume precluded the accurate
identification of macrometastases (≥2 mm) in lymph nodes.2
The positive predictive value of one step nucleic acid
amplification compared with histology was only 0.79, and the
authors concluded that up to 21% of patients found to have
positive lymph nodes using this method had micrometastases
and therefore did not require axillary clearance. It is clearly time
for NICE to re-evaluate its guidance on one step nucleic acid
amplification.
Is treatment necessary?
Doubts that patients with positive nodes require additional
treatment stem from a pivotal US trial with 25 year follow-up.3
The National Surgical Adjuvant Breast and Bowel Project
(NSABP) B-04 trial found no survival benefit for patients with
clinically node negative breast cancer who received axillary
radiotherapy or axillary clearance compared with those whose
nodes were treated only when they became palpable. More
recently, the American College of Surgeons Oncology Group
Z0011 trial evaluated axillary node dissection in clinically node
negative patients having breast conserving surgery, whole breast
radiotherapy, and adjuvant systemic treatment.4 It compared the
outcomes in patients with one or two positive sentinel nodes
randomised to axillary lymph node dissection or sentinel lymph
node biopsy alone. At median follow-up of 6.3 years there was
no difference in the axillary recurrence rates between groups
(0.5% versus 0.9%, respectively) and no improvement in
survival with axillary lymph node dissection. Although this trial
recruited fewer patients than originally planned, the findings
were statistically valid.4 5The death rate was low in both arms
of the trial, almost certainly because patients received effective
systemic therapy, thus reducing the chances that axillary surgery
could have influenced survival. Axillary lymph node dissection
did, however, significantly increase the rate of lymphoedema.5
Two trials have since confirmed that patients with small volume
axillary nodal disease do not require axillary lymph node
dissection. The NSABP B-32 trial randomised 5600 patients
with clinically node negative breast cancer to receive either
axillary lymph node dissection or sentinel lymph node biopsy
alone.6 Over 4000 of the patients were pathologically node
negative on haematoxylin and eosin staining, and
immunohistochemistry identified axillary nodal micrometastases
or isolated tumour cells in 616 of these patients. At 10 years
there was no significant benefit in local control or overall
survival in patients with micrometastases who had axillary
clearance compared with those who had sentinel node biopsy
alone. Similarly, a large randomised European trial found no
benefits in disease control or survival for axillary node dissection
compared with sentinel node biopsy alone in patients with
micrometastases (<2 mm).7 These and other studies led the
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American Society of Clinical Oncology to advise that patients
with one to two positive nodes on biopsy who have breast
conserving surgery, whole breast radiotherapy, and similar
clinical and pathological characteristics to those enrolled in the
Z0011 trial do not require routine axillary lymph node
clearance.8
Alternative treatment
Axillary radiotherapy is an alternative to complete axillary
lymph node dissection for patients with sentinel lymph node
metastases. Studies performed 30 years ago compared axillary
radiotherapy with axillary lymph node dissection and showed
no difference in survival.9 10More recently, a large multicentre
European study compared axillary radiotherapy with axillary
lymph node dissection in patients with a positive sentinel node
and showed no significant difference in the rates of axillary
recurrence and survival.11However, the lymphoedema rate with
axillary radiotherapy was half that seen in patients treated with
lymph node dissection. Therefore, for women who are likely to
benefit from axillary treatment, radiotherapy is a viable
alternative to axillary dissection, offering similar rates of disease
control but lower rates of morbidity.
Many centres in the United States have abandoned intraoperative
assessment of sentinel nodes, but one step nucleic acid
amplification continues to be widely used in the United
Kingdom. Given the results from randomised trials, the
guidelines from the American Society of Clinical Oncology,
and the alternative options available for patients with diseased
nodes, it seems unnecessary for patients to have intraoperative
axillary lymph node assessment. It is imperative that decisions
about how to treat axillary nodal disease are made with
knowledge of tumour biology, the burden of disease in the
sentinel nodes, and any planned radiotherapy and systemic
therapy. Most importantly, patients need to participate in these
decisions. Intraoperative frozen section analysis of breast
tumours was abandoned long ago because it denied patients the
opportunity to contribute to their treatment planning. It is now
time to do the same with intraoperative sentinel lymph node
assessment.
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